Responsabilidade ética do médico veterinário no comércio de medicamentos a base da Cannabis Sativa

Abstract

The therapeutic use of Cannabis sativa has gained prominence in both human and veterinary medicine due to the pharmacological properties of its cannabinoids. The discovery of the endocannabinoid system demonstrated its importance in maintaining homeostasis in several species, including dogs and cats, allowing the potential use of cannabis-derived products in the treatment of cardiovascular, respiratory, metabolic, dermatological, and oncological disorders, as well as pain management. Despite scientific advances, Brazilian veterinary medicine still faces legal limitations regarding the prescription and commercialization of these products. This study aimed to analyze the ethical responsibility and legal reality of veterinarians concerning the use of Cannabis sativa-based medications. A bibliographic review was conducted through the analysis of scientific literature, current legislation, and regulations related to the topic. The findings indicate that, although there is evidence supporting the therapeutic benefits of cannabinoids for animals, the lack of specific regulations creates legal uncertainty for veterinary professionals. It is concluded that the formal inclusion of veterinary medicine among the professions authorized to prescribe cannabis-derived products may increase treatment safety, encourage scientific research, and promote greater quality control and regulatory oversight of products intended for animal health.